HOME¥NEWS&EVENTS SYMPOSIA RESEARCH / GRANT OTHER ACTIVITIES CONTACT HIRF
 
About HIRF
  1. Mission
  2. Management
  3. History
  4. Affiliates

About ICVS

  • 2001 Tokyo
  • 2003 Beijing
  • 2004 London
  • 2006 Washington DC
  • 2007 Vienna
  • 2008 New York
Research
Grant Programs
  • Clinical Trials
  • Education
  • Training
  • Publication

Recommended Links

Contact HIRF

International Cancer Vaccine Symposium
In Washington DC 2006
gCurrent Clinical and Laboratory Advances in Cancer Vaccines and Immunotherapiesh
February 5-7, 2006 North Bethesda Marriott Hotel, Bethesda, Maryland, USA

SUNDAY 5 FEBRUARY 2006

18:30 Speakers' Reception/Dinner at North Bethesda Marriott Hotel

MONDAY 6 FEBRUARY 2006

7:30 Registration

OPENING:

8:30 Welcome Address
Dr. Lowell T. Harmison, Chairman, World Immuno-Society for Health, Switzerland Dr. Kenichiro Hasumi, Chairman, Hasumi International Research Foundation, USA

KEYNOTE SPEAKER:

8:40 On Immunity Against Viruses and Tumours
Professor Rolf Zinkernagel, University Hospital, Zurich, Switzerland

SESSION 1: chaired by Dr. Jeffrey Schlom, National Cancer Institute, NIH, USA

10:00 A Novel DNA-based Vaccines for Cancer Therapy
Dr. Ralph A. Reisfeld, The Scripps Research Institute, USA
10:30 Design and Development of Recombinant Vaccines for the Therapy of Carcinomas
Dr. Jeffrey Schlom, National Cancer Institute, NIH, USA
11:00 Immunotherapy of Established Papilloma Virus-Induced (pre-)Malignant Lesions in Mice, Rabbits and Patients
Professor Cornelis Melief, University Hospital Leiden, the Netherlands
11:30 Design and Optimization of Peptide-Based Vaccines for Cancer
Dr. Esteban Celis, Louisiana State University Health Science Center, USA

SPECIAL REMARKS:

13:00 Current Research and Drug Discovery in a New Era
Dr. John E. Niederhuber, Deputy Director, National Cancer Institute, NIH, USA

SESSION 2: chaired by Dr. Tyler Curiel, Tulane Medical School, USA

13:30 Tumour Cell-Dendritic Cell Fusion Vaccine
Dr. David Avigan, Beth Israel Deaconess Medical Center, USA
14:00 Overcoming Negative Regulation to Enhance Cancer Vaccines and Immunosurveillance
Dr. Jay Berzofsky, National Cancer Institute, NIH, USA
14:30 Regulatory T Cell Depletion in Cancer: Immunologic and Clinical Correlates
Dr. Tyler Curiel, Tulane Medical School, USA
15:00 Autoimmunity and Vaccination in Melanoma
Dr. Jeffrey S. Weber, USC/Norris Comprehensive Cancer Institute, USA

SESSION 3: chaired by Dr. Dean Mann, University of Maryland Baltimore, USA

15:50 Prevention of HPV Infection and Cervical Cancer
Dr .Douglas Lowy, National Cancer Institute, NIH, USA
16:20 Innate Immunity in Cancer and Hematopoietic Cell Transplantation
Dr. Jeffrey S. Miller, University of Minnesota, USA
16:50 Antigens Targeted in the Successful Immunosurveillance of Tumor Progression are Candidates for Prophylactic Cancer Vaccines
Dr. Olivera gOljah J. Finn, University of Pittsburgh, USA

TUESDAY 7 FEBRUARY 2006

SESSION 4: chaired by Dr. Ralph A. Reisfeld, The Scripps Research Institute, USA

8:30 Optimisation of Cancer Vaccines for Therapy of The Common Solid Tumours
Professor Angus Dalgliesh, St. Georgefs University of London, United Kingdom
9:00 Vaccines for Prostate Cancer ? a Translational Journey from Conception to Phase III Clinical Studies
Dr. James L. Gulley, National Cancer Institute, NIH, USA
9:30 Heat-Shock Proteins: Immunobiology and Use in Cancer Vaccines
Professor Giorgio Parmiani, Istituto Nazionale Tumori, Milano, Italy

SESSION 5: chaired by Dr. Ronald Levy, Stanford University School of Medicine, USA

10:20 Therapeutic Vaccination for Lymphoid Malignancy
Dr. Ronald Levy, Stanford University School of Medicine, USA
10:50 Dendritic Cell Vaccination and Amplification Strategies
Professor Gerold Schuler, University Hospital of Erlangen, Germany
11:20 Imiquimod-Induced Regression of Cutaneous Neoplasms: Cellular and Molecular Mechanisms
Professor Georg Stingl, University of Vienna Medical School, Austria
11:50 Dendritic Cell as Therapeutic Vaccines in Cancer
Dr. Karoline Palucka, Baylor Institute for Immunology Research, USA

SESSION 6: chaired by Dr. Elizabeth M. Jaffe, Johns Hopkins, USA

13:20 Tipping the Immune System Balance in Favor of Effective Anti-Cancer Interventions
Dr. Elizabeth M. Jaffe, Johns Hopkins, USA
13:50 Recent Progress in Human Cancer Immunotherapy
Dr. Steven A. Rosenberg, National Cancer Institute, NIH, USA
14:20 Checkpoint Blockade in Cancer Immunotherapy
Dr. James P. Allison, Howard Hughes Medical Institute/Memorial Sloan-Kettering Cancer Center, USA

SESSION 7: chaired by Dr. Crystal L. Mackall, National Cancer Institute, NIH, USA

15:10 The Present Status of Active Specific Immunotherapy with Canvaxin Whole-Cell Vaccine after Resection of Metastatic Melanoma
Dr. Donald L. Morton, John Wayne Cancer Institute, USA
15:40 Evaluation of Antigens for Vaccination Against Prostate Cancer
Professor Peter Rieber, Technical University Dresden, Germany
16:10 Contrasting IL-2 and IL-7 in Cancer Immunotherapy and Immune Reconstitution
Dr. Crystal L. Mackall, National Cancer Institute, NIH, USA

FUTURE VIEWS:

16:40 Professor Hans Wigzell, Karolinska Institutet, Sweden

CLOSING: